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Background: Mevalonate kinase deficiency (MKD) is caused by mutations in the MVK gene, encoding the second
enzyme of mevalonate pathway, which results in subsequent shortage of downstream compounds, and starts in
childhood with febrile attacks, skin, joint, and gastrointestinal symptoms, sometimes induced by vaccinations.
Methods: For a history of early-onset corticosteroid-induced reduction of bone mineral density in a 14-year-old boy
with MKD, who also had presented three bone fractures, we administered weekly oral alendronate, a drug widely
used in the management of osteoporosis and other high bone turnover diseases, which blocks mevalonate and
halts the prenylation process.
Results: All of the patient’s MKD clinical and laboratory abnormalities were resolved after starting alendronate
treatment.
Conclusions: This observation appears enigmatic, since alendronate should reinforce the metabolic block
characterizing MKD, but is crucial because of the ultimate improvement shown by this patient. The anti-inflammatory
properties of bisphosphonates are a new question for debate among physicians across various specialties, and requires
further biochemical and clinical investigation.
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The so-called “mevalonate pathway” produces the pre-
cursors of several biomolecules, as well as crucial end-
products for functions ranging from cellular signalling
and membrane integrity to protein prenylation and glyco-
sylation. Many enzymes serve as catalysts along this multi-
step pathway and its various branches, and several inhibitor
drugs target some of these enzymes, including the group of
bisphosphonates, which inhibit farnesyl diphosphate syn-
thase, usually prescribed to prevent bone resorption [1].
Alendronate is a second-generation nitrogen-containing
bisphosphonate used for the treatment of metabolic bone
disorders, osteoporosis, and Paget’s disease [2,3]. A rare
hereditary autoinflammatory disorder, involving the sec-
ond enzyme in the mevalonate/cholesterol pathway, is
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stated.in the MVK gene encoding the enzyme mevalonate kinase
[4]. This disease, characterized by recurrent episodes of
fever that begin during infancy and usually improve in
late adolescence or adulthood, is now considered along
a spectrum ranging from a milder form, called hyper-
immunoglobulinemia D (or HIDS for short), to the most
severe form, called mevalonic aciduria (or MVA) [5].
HIDS was first reported when high serum IgD levels
and large numbers of plasma cells with cytoplasmic IgD
were discovered in the bone marrow of Dutch patients
with recurrent fever episodes, while MVA was the first
defect recognized in the cholesterol pathway. Recently,
biochemists have obtained in vivo and in vitro models
of MKD by treating mouse cells with alendronate and
other aminobisphosphonates, inhibiting an enzyme lo-
cated at a point further down the pathway than meva-
lonate kinase [6,7]. These models suggest that alendronate
should increase the biochemical abnormality, and should
thus be contraindicated in patients with MKD. But this
did not seem to be the case with our young patient.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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In July 2012, a 14-year-old boy was admitted to our Unit
with a long history of recurrent high fevers up to 40°C
(at least twice a month), combined with abdominal pain,
diarrhea, vomiting, aphthous stomatitis, erythematous
pharyngitis and, sometimes, chest pain. His symptoms
had begun in early infancy (at about 6 months). His first
fever attacks were also characterized by a remitting pustu-
lar rash all over his body; in general, the attacks lasted
around 5–6 days. Over the past 13 years, his fevers had
been treated with betamethasone up to 4 mg/daily, some-
times in combination with ibuprofen (8 mg/kg/dose). At
age 11, the boy had developed three bone fractures in a 3-
month-period, caused by minor traumas or normal daily
activities, involving the right wrist, the distal phalanx of
the right thumb and the distal phalanx of the left big toe.
During our first clinical examination, the boy was alert.
His temperature was normal, as was his blood pressure
and general physical examination. His growth had been
normal, and he was between the 25th and 50th percentile
in height and weight for age. Evaluation of antibodies
in a non-symptomatic period showed increased IgD
(184 IU/ml, n.v. <100 IU/ml) and normal IgA. Labora-
tory investigations performed during a febrile attack
showed: erythrocyte sedimentation rate (ESR): 51 mm/h
(n.v. <25), C-reactive protein (CRP) 1.3 mg/dl (n.v. <0.5),
serum amyloid-A (SAA) 130.8 mg/L (n.v. <10), and slight
proteinuria (0.36 g/24 hours). A full diagnostic work-up,
including serologic tests, complement fractions, and
anti-nuclear autoantibody tests was negative. A metabolic
screening during the fever attack showed increased
mevalonic acid in the urine (15.6 mmol/mol creatinine,
n.v. <1), while bone marrow aspiration performed
during a hospital stay ruled out any blood diseases.
After providing a written consent for genetic testing,
the boy was tested for mutations in the MEFV gene, the
TNFRSF1A gene, and the MVK gene, to check for fami-
lial Mediterranean fever, tumor necrosis factor receptor-
associated periodic syndrome, and MKD. A homozygous
V377I MVK mutation was found, confirming the diagno-
sis of MKD; the other genetic analyses were negative.
Due to his history of bone fractures and long-term use
of betamethasone administration, leading to a cumulative
steroid dose of about 3.5 g administered in the past 13 years,
we performed bone dual-energy X-ray absorptiometry
(DEXA) to evaluate bone mineral density (BMD). The
test showed severe osteoporosis at the femoral necks
(Z-score −3.1) and lumbar spine (Z-score −3.1) according
to World Health Organization standards. After ruling out
other possible causes of secondary osteoporosis, i.e. en-
docrine disorders, celiac disease, inflammatory bowel
diseases, and sarcoidosis, the patient was started on oral
alendronate (70 mg/week) in order to improve his skeletal
status and potentially avoid further bone fractures.Surprisingly, for the first time in his life, the boy had no
further febrile attacks and no inflammatory episodes over
the following nine months, and needed no other treatment
in that period. In addition, SAA levels, checked monthly,
returned to normal. He even received a flu vaccination
with no flare-up of fever.
Since the boy’s mutation is regarded as a low-penetrance
one [8], his evolution towards remission of MKD was
thought to be spontaneous, and by mutual agreement with
his parents, alendronate therapy was withdrawn. Strikingly,
four weeks later, a typical MKD fever attack occurred, and
alendronate was subsequently resumed during a prolonged
fever episode, leading to the resolution of fever. To date,
there is no sign of disease relapse four months after having
restarted weekly alendronate therapy.
Discussion
Most of our knowledge about the mevalonate pathway is
currently focused on the cholesterol synthesis branch,
the target of cholesterol-lowering statin drugs; less is
known about the function and regulation of the non-
cholesterol-related branches. MKD, which is caused by
the interruption of the mevalonate/cholesterol biosynthetic
pathway, remains an obscure disease, with recurring fever
attacks triggered mainly by vaccinations, infections, emo-
tional stress, trauma and surgery, combined with varying
other symptoms including abdominal signs, arthralgia,
lymphadenopathy, and heterogeneous skin lesions [9,10].
A clear biological understanding of the inflammatory
attacks that occur in MKD is still lacking, and macro-
pahage activation syndrome has been reported as a poten-
tial complication of MKD febrile flare [11]. Isoprenoids
including farnesyl- and geranylgeranyl-pyrophosphate play
a key role in the prenylation of many proteins involved
in cytoskeletal functions and vesicular trafficking [12]:
indeed, a deficiency of isoprenoids may trigger interleukin-
1β (IL-1β) production by peripheral blood mononuclear
cells, while these same cells, drawn from MKD patients
exposed to geranylgeranyl pyrophosphate, produce rela-
tively little IL-1β [13,14].
To date, more than 170 MVK gene variants have been
described, though only a portion of these are thought to
be clearly disease-causing [15]. No definite therapy exists
for MKD, and no studies have been performed to establish
evidence-based treatment strategies. Many patients may
benefit from on-demand administration of non-steroidal
anti-inflammatory drugs and corticosteroids, especially at
high doses, but these treatments bring the risk of severe
side effects, including meta-steroidal osteopenia or osteo-
porosis after prolonged use. Anti-IL-1 or anti-tumor
necrosis factor-α biological agents are an effective alterna-
tive to high doses of corticosteroids in selected patients,
although their drawbacks include increased risk of
secondary infections and high costs [16].
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containing bisphosphonate, in an attempt to counteract
the glucocorticoid-related severe reduction of BMD,
even though in vitro studies had shown that bisphos-
phonates could worsen fever attacks in MKD by further
inhibiting a metabolic pathway that was already patho-
logically interrupted [17]. This treatment brought about
an unexpected remission of all MKD pathological symp-
toms and laboratory abnormalities. We then decided to
stop alendronate in order to determine whether the im-
provement of the MKD clinical picture was in fact spon-
taneous, but we observed a disease relapse after four
weeks. The resumption of alendronate during a fever
attack ended the attack in only 2 days, and a stable dis-
ease remission was maintained at a 4-month follow-up.
In the past, alendronate has been reported to have both
pro-inflammatory and anti-inflammatory effects. Deng
and colleagues found that alendronate increases IL-1β in
tissues (liver, spleen, and lung), but, strangely, not in the
blood [18]. Later, Shikama and colleagues explained this
phenomenon when they discovered that alendronate
directly stimulates macrophage cells to produce pro-IL-
1β, though the release of mature IL-1β was undetectable
in consequence of a poor activation of caspase-1, the IL-1
converting enzyme which yields the bioactive IL-1β [19].
Bisphosphonates have also demonstrated specific anti-
inflammatory effects, inhibiting macrophage nitric oxide
production in a dose-dependent manner [20]. In particu-
lar, nitrogen-containing bisphosphonates seem to induce a
significant reduction of synovial lining macrophage cells,
resulting in a localized decreased expression of adhesion
molecules in the synovial space of patients with rheu-
matoid arthritis [21]. The induction of apoptosis by
different bisphosphonates may have a central role in explain-
ing their anti-inflammatory effects – in fact, MKD
patients’ lymphocytes have shown a defective apoptosis
during fever remission, explaining the risk of overblown
inflammation after minor triggers [22]. At last, alendro-
nate has also exhibited a dose-dependent inhibition of
the production of IL-1β by activated monocytes [23],
although further studies are required to confirm the
inhibitory effect of this agent on cytokine production
and its consequences on bone resorption.
In conclusion, as bisphosphonates inhibit a metabolic
pathway already pathologically interrupted in MKD pa-
tients, theoretically they should be contraindicated in these
subjects. Nevertheless, alendronate anti-inflammatory
effects should have prevailed in our patient giving rise to
the resolution of his periodic febrile attacks. We honestly
cannot explain this result at a pathogenetic level, and
further in vivo and in vitro studies should be performed to
clarify the exact role of bisphosphonates on MKD. Func-
tional studies are ongoing in our laboratories. The debate is
open about the potential use of a safe, inexpensive, andeasily administered treatment that should control the exas-
perating recurrent inflammatory attacks of MKD patients.
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